Magnetic resonance imaging of the spleen: influence of the dose of a gadolinium chelate on the degree of parenchymal enhancement.
OBJECTIVE
We examined how the dose of an intravenous (i.v.) gadolinium chelate (gadoterate meglumine) would affect the degree of splenic enhancement on magnetic resonance (MR) imaging.


METHODS
Forty patients had breath-hold three-dimensional fast spoiled gradient-recalled MR imaging of the abdomen done before and after i.v. administration of one of four doses of gadoterate meglumine (0.075, 0.100, 0.150, or 0.200 mmol/kg). Peak enhancement values and the time to peak enhancement of splenic parenchyma were compared (values are reported as means +/- standard deviations).


RESULTS
Peak enhancement values were 154 +/- 99%, 215 +/- 109%, 276 +/- 170%, and 349 +/- 144 +/- for the doses of 0.075, 0.100, 0.150, and 0.200 mmol/kg, respectively. A high correlation was found between the dose and mean peak enhancement values (R2 = .998), which varied as a linear function of the dose. The mean times to peak enhancement obtained with the four doses were not significantly different.


CONCLUSIONS
Using doses ranging from 0.075 to 0.200 mmol/kg, the peak enhancement of splenic parenchyma is a linear function of the dose of the gadolinium chelate administered. The time to peak splenic enhancement is not affected.
Soyer
P
P
Department of Radiology, Hopital Foch, Suresnes, France.
Scherrer
A
A
D000328:Adult; D000368:Aged; D003287:Contrast Media / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D008279:Magnetic Resonance Imaging; D008297:Male; D008536:Meglumine / Q000008:administration & dosage*; D008875:Middle Aged; D009942:Organometallic Compounds / Q000008:administration & dosage*; D011446:Prospective Studies; D013154:Spleen / Q000033:anatomy & histology*
D003287:Contrast Media; D009942:Organometallic Compounds; D008536:Meglumine; C072417:gadoterate meglumine